PET Imaging Helps Guide Alzheimer’s Treatment Decisions
Molecular imaging is helping clinicians determine treatment eligibility and monitor progress for Alzheimer’s patients.
Updated on Oct. 29, 2026 in Alzheimer’s
Live Poll
Would you pay out-of-pocket for advanced medical imaging to help guide your own healthcare treatment decisions?
At the 2026 European Association of Nuclear Medicine congress in Vienna, experts discussed how PET imaging can guide anti-amyloid therapy decisions. This diagnostic approach helps determine patient eligibility for treatments and tracks amyloid burden to support care decisions.
Why it matters
Molecular imaging provides a way to personalize Alzheimer's care by identifying which patients are most likely to benefit from specific therapies. These tools are increasingly vital for tracking treatment response and deciding when to discontinue medication.
Clinical consensus identifies amyloid PET as a key tool for determining patient eligibility for anti-amyloid therapies and monitoring disease progression. However, widespread clinical use remains hindered by significant barriers including limited tracer availability and lack of reimbursement.
The players
European Association of Nuclear Medicine
A professional organization that advances the field of nuclear medicine through research and clinical education.
The details
Clinicians utilize amyloid PET scans to verify the presence of amyloid plaque, which serves as a primary marker for evaluating therapy eligibility. Additionally, tau PET imaging is employed to assess tau pathology, helping medical teams personalize treatment plans and forecast clinical benefits. While neuroinflammation PET remains a research-focused tool for now, experts anticipate that tau imaging will play an increasingly prominent role in future treatment strategies.
Timeline
2026: European Association of Nuclear Medicine congress in Vienna.
Health Landscape
The shift toward molecular imaging represents an evolution in how clinicians manage Alzheimer's, moving from symptom-based observation to targeted biomarker assessment. This transition is essential for implementing personalized treatment strategies as new anti-amyloid therapies become available.
If you or a loved one are considering anti-amyloid treatments, talk to your physician about whether PET imaging is available or appropriate for your specific case. Be aware that access to these imaging tools varies significantly due to local reimbursement and infrastructure constraints.
The takeaway
Molecular imaging serves as a critical tool for navigating the complexities of Alzheimer's treatment. Consult your neurologist to understand how specific diagnostic biomarkers might inform personalized treatment decisions or future therapeutic adjustments.
Further reading
For more on diagnostic developments, visit our Alzheimer’s section.
Source note: This article includes information reported by AuntMinnieEurope.
Live Poll
Would you pay out-of-pocket for advanced medical imaging to help guide your own healthcare treatment decisions?
